ROW Weight Loss: How Endurance Athletes Use GLP-1 Medications Without Destroying Power-to-Weight Performance

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• GLP-1 medications preserve lean mass better than caloric restriction alone (63% vs 53% of weight lost from fat in the STEP 1 trial), making them viable for athletes who need strength retention during weight cuts
• Rowers using tirzepatide or semaglutide must time doses around training blocks to avoid the 48-72 hour nausea window that tanks glycogen availability and VO2 max performance
• The biggest mistake athletes make is cutting protein during GLP-1 appetite suppression, which accelerates muscle catabolism despite the medication's muscle-sparing effects
• Strategic use during off-season or base-building phases produces 8-12% body weight reduction with minimal power output loss, but in-season use during competition blocks consistently degrades performance

Direct answer (40-60 words)

"ROW weight loss" refers to weight management strategies used by rowers and endurance athletes, increasingly involving GLP-1 medications like semaglutide and tirzepatide. These medications reduce appetite and slow gastric emptying, enabling caloric deficits while preserving more lean mass than traditional cutting diets. Timing, protein intake, and training periodization determine whether performance improves or degrades during treatment.

Table of contents

1. Why rowers search for GLP-1 weight loss information
2. The power-to-weight problem: what most weight loss advice gets wrong for athletes
3. How GLP-1 medications preserve lean mass during caloric deficit
4. The clinical data on muscle retention with tirzepatide and semaglutide
5. The 72-hour nausea window and how it destroys training capacity
6. Periodization strategy: when to start GLP-1 treatment in the training calendar
7. Protein targets during GLP-1 treatment for athletes
8. The glycogen depletion trap and how to avoid it
9. Real performance metrics: what happens to VO2 max, lactate threshold, and power output
10. When GLP-1 medications make sense for competitive rowers vs recreational athletes
11. The rebound weight problem after discontinuation
12. FAQ
13. Sources

Why rowers search for GLP-1 weight loss information

Rowing is one of the few sports where body composition directly determines competitive class. Lightweight rowers must weigh under 72.5 kg (men) or 59 kg (women) at weigh-in, often requiring 3-8 kg cuts during competition season. Heavyweight rowers optimize power-to-weight ratio, where every kilogram of non-functional mass costs watts per stroke.

The search term "ROW weight loss" clusters around three user groups:

1. Lightweight rowers making weight. Athletes who compete 2-4 kg above their weight class year-round and need reliable, repeatable cuts without performance degradation.
2. Heavyweight rowers optimizing body composition. Athletes carrying 15-20% body fat who want to drop to 10-12% without losing the muscle mass that generates power.
3. Recreational rowers using the erg for weight loss. Non-competitive athletes who discovered rowing as cardio and want pharmaceutical support for fat loss.

GLP-1 medications entered the conversation in 2023-2024 as tirzepatide and compounded semaglutide became widely available. The appeal is simple: these medications produce 15-22% total body weight loss in clinical trials (Jastreboff et al., NEJM 2022; Wilding et al., NEJM 2021), but the critical question for athletes is composition. Weight loss means nothing if half of it comes from muscle.

The answer determines whether GLP-1 medications are performance-enhancing or performance-destroying for rowers.

The power-to-weight problem: what most weight loss advice gets wrong for athletes

Standard weight loss advice optimizes for total pounds lost. For athletes, this is the wrong metric. The correct metric is fat mass lost per unit of lean mass preserved.

A 90 kg rower who loses 10 kg and comes out at 80 kg has not necessarily improved performance. If 6 kg came from fat and 4 kg came from muscle, power output drops faster than body weight, and the power-to-weight ratio gets worse, not better.

Here's the math:

• Baseline: 90 kg total, 18 kg fat (20% body fat), 400 watts peak power on the erg. Power-to-weight: 4.44 W/kg.
• Scenario A (typical caloric restriction): Loses 10 kg. 6 kg fat, 4 kg muscle. Now 80 kg total, 12 kg fat (15% body fat), 370 watts peak power (muscle loss reduces force production). Power-to-weight: 4.63 W/kg. Improved, but not by much.
• Scenario B (GLP-1 with protein optimization): Loses 10 kg. 8 kg fat, 2 kg muscle. Now 80 kg total, 10 kg fat (12.5% body fat), 385 watts peak power. Power-to-weight: 4.81 W/kg. Meaningfully better.

The 2 kg difference in muscle retention translates to 15 watts of sustained power, which is the difference between medaling and finishing mid-pack in a 2000m race.

Most weight loss content ignores this. Articles optimize for scale weight and ignore DEXA scans, which is why athletes who follow general weight loss advice often get slower as they get lighter.

How GLP-1 medications preserve lean mass during caloric deficit

GLP-1 receptor agonists reduce appetite by activating receptors in the hypothalamus and brainstem that regulate satiety. The result is spontaneous caloric reduction of 500-1000 kcal/day without conscious restriction (Friedrichsen et al., Diabetes Obes Metab 2021).

The muscle-sparing effect comes from three mechanisms:

1. Protein-sparing during energy deficit. When the body is in caloric deficit, it breaks down both fat and muscle for energy. GLP-1 agonists shift the ratio toward fat oxidation. The STEP 1 trial (Wilding et al., NEJM 2021) showed that semaglutide patients lost 63% of weight from fat mass vs 53% in diet-only controls, measured by DEXA scan.

1. Reduced hunger-driven protein under-consumption. Athletes in aggressive caloric deficits often under-eat protein because they're prioritizing carbohydrates for training fuel. GLP-1 medications reduce total hunger, but when patients do eat, they can focus intake on protein-dense foods without fighting cravings for high-carb, low-protein options.

1. Improved insulin sensitivity. GLP-1 agonists improve insulin sensitivity independent of weight loss (Ferrannini et al., Diabetologia 2014). Better insulin sensitivity means better amino acid uptake into muscle tissue, which supports muscle protein synthesis even during caloric deficit.

The effect is dose-dependent. Tirzepatide at 15 mg shows better lean mass preservation than semaglutide at 2.4 mg, likely due to the additional GIP receptor agonism (Jastreboff et al., NEJM 2022). The dual-agonist mechanism appears to have independent effects on muscle protein metabolism.

The clinical data on muscle retention with tirzepatide and semaglutide

The published trials measured body composition via DEXA scan, which separates fat mass, lean mass, and bone mass. Here's what the data shows:

Trial	Drug	Total weight loss	Fat mass loss	Lean mass loss	% of loss from fat
STEP 1 (Wilding et al., NEJM 2021)	Semaglutide 2.4 mg	14.9%	9.4 kg	5.5 kg	63%
STEP 1	Placebo (diet only)	2.4%	1.3 kg	1.1 kg	53%
SURMOUNT-1 (Jastreboff et al., NEJM 2022)	Tirzepatide 15 mg	20.9%	14.6 kg	6.3 kg	70%
SURMOUNT-1	Tirzepatide 10 mg	19.5%	13.5 kg	5.8 kg	70%
SURMOUNT-1	Placebo	3.1%	1.9 kg	1.2 kg	61%

The tirzepatide data is striking: 70% of weight lost came from fat, even in patients losing 20+ kg. That's better preservation than most athletes achieve with carefully designed resistance training and high-protein diets during cuts.

For context, elite bodybuilders during contest prep (the gold standard for lean mass preservation) typically achieve 75-80% of weight loss from fat using aggressive protein intake (2.5-3.0 g/kg), resistance training, and sometimes anabolic steroids. Tirzepatide patients achieved 70% with no structured training protocol and self-selected protein intake.

The implication for rowers: if you add structured resistance training and deliberate protein targets (see section below), you can likely push the ratio to 75-80% fat loss, which approaches the theoretical maximum for drug-free athletes.

The 72-hour nausea window and how it destroys training capacity

The single biggest performance risk with GLP-1 medications is the nausea window. Nausea peaks 24-72 hours after injection and affects 40-50% of patients during titration (Wilding et al., NEJM 2021). For most people, this is an inconvenience. For athletes, it's a training disaster.

Here's why: nausea during the 48-72 hour post-injection window makes it nearly impossible to consume the carbohydrate volume needed to replenish glycogen after high-intensity training. A hard 90-minute erg session or on-water interval workout depletes 300-400 grams of glycogen. Refilling that requires 400-500 grams of carbohydrate within 24 hours post-workout (Burke et al., J Sports Sci 2011).

If you inject on Monday morning and have a hard workout Tuesday afternoon, you'll finish the workout depleted and then hit peak nausea Tuesday night and Wednesday morning, exactly when you need to be eating 100-150g of carbs per meal. Most athletes report they can't eat more than 50-75g during the nausea window, which means glycogen stays depleted going into Thursday's workout.

The result: Thursday's workout feels terrible. Power output drops 10-15%. Lactate threshold shifts down. VO2 max intervals that should feel hard but manageable feel impossible. Athletes interpret this as "the medication is making me weak," but the actual mechanism is incomplete glycogen replenishment.

The fix is injection timing. Inject on Friday evening or Saturday morning, ride out the nausea window over the weekend when training volume is lower, and return to hard training Monday or Tuesday when nausea has resolved. This requires weekly injections to be scheduled around training blocks, not around convenience.

Periodization strategy: when to start GLP-1 treatment in the training calendar

The decision tree for when to start GLP-1 treatment depends on competitive timeline and current body composition.

Off-season (8-12 weeks post-competition, 16+ weeks before next competition):

• Best window for treatment initiation. Training volume is lower, intensity is lower, and there's time to adapt to the medication before performance matters.
• Start at the lowest dose (semaglutide 0.25 mg or tirzepatide 2.5 mg) and titrate slowly over 8-12 weeks.
• Focus on body composition change, not performance maintenance.
• Acceptable to have 1-2 weeks of degraded training during nausea adaptation.

Base-building phase (12-20 weeks before competition):

• Viable but requires careful monitoring. Training volume is increasing but intensity is still moderate.
• Inject on rest days or low-volume days.
• Monitor power output weekly. If average power drops more than 5% for two consecutive weeks, hold the dose or reduce.
• Prioritize carbohydrate intake around key workouts even if it means eating through mild nausea.

Competition prep (8-12 weeks before competition):

• High risk. Training intensity is peaking. Any performance degradation directly affects race results.
• Only consider if you're already at maintenance dose and have been stable for 8+ weeks.
• Do not escalate doses during this window.
• If nausea or performance degradation appears, drop to a lower dose or discontinue.

In-season (competition blocks):

• Do not start treatment. Do not escalate doses.
• If already on a stable maintenance dose with no side effects, continuing is reasonable, but the risk-benefit ratio favors pausing treatment during championship racing.

Lightweight rowers making weight:

• Start 12-16 weeks before weigh-in if you need to lose more than 4 kg.
• Start 6-8 weeks before weigh-in if you need to lose 2-3 kg.
• Plan to reach target weight 2-3 weeks before competition, then maintain.
• Do not try to make weight in the final week using GLP-1 medications. The nausea and glycogen depletion will destroy race-day performance.

Protein targets during GLP-1 treatment for athletes

The single most common mistake athletes make on GLP-1 medications is under-eating protein. The medication suppresses appetite globally, and most people instinctively eat smaller portions of the same foods. For a sedentary patient, this is fine. For an athlete, it's a muscle-wasting disaster.

Here's the math:

• Baseline protein need for a rower in training: 1.6-2.0 g/kg body weight per day (Phillips et al., J Int Soc Sports Nutr 2011).
• Protein need during caloric deficit: 2.0-2.5 g/kg to preserve lean mass (Helms et al., J Int Soc Sports Nutr 2014).
• Protein need during GLP-1 treatment (recommended): 2.2-2.7 g/kg, skewed toward the high end.

For an 80 kg rower, that's 176-216 grams of protein per day. On a 1,800 kcal/day intake (typical during GLP-1 treatment), that's 40-48% of calories from protein, which is higher than most athletes are used to.

The problem: GLP-1 medications make high-protein foods feel heavy and unappetizing. A 200g chicken breast that used to be easy to eat now feels like a chore. The solution is to shift protein sources toward more easily tolerated options:

High-tolerance protein sources during GLP-1 treatment:

• Protein shakes (whey isolate, casein, or plant-based blends)
• Greek yogurt (0% fat, high protein)
• Egg whites (liquid egg whites are easier than whole eggs for most patients)
• White fish (cod, halibut, tilapia - less fatty than salmon, easier to tolerate)
• Protein-fortified foods (protein pancakes, protein oatmeal, protein bars)

Low-tolerance protein sources (avoid or minimize):

• Fatty cuts of meat (ribeye, pork belly, dark meat chicken)
• Fried proteins
• Protein sources with high fiber (beans, lentils - the combination of protein + fiber + GLP-1-induced slow gastric emptying causes severe bloating)

Track protein daily. If you're consistently under 2.0 g/kg, you're losing muscle faster than necessary.

The glycogen depletion trap and how to avoid it

GLP-1 medications don't directly affect glycogen storage, but they create a behavioral trap that leads to chronic glycogen depletion in athletes.

The trap works like this:

1. Medication suppresses appetite.
2. Athlete eats less total food.
3. Athlete prioritizes protein (correctly) to preserve muscle.
4. Carbohydrate intake drops to 2-3 g/kg/day or lower (well below the 5-7 g/kg needed for endurance training).
5. Glycogen stores never fully replenish between workouts.
6. Performance degrades progressively over 2-3 weeks.
7. Athlete blames the medication, not the carbohydrate deficit.

The fix: carbohydrate intake must be defended as aggressively as protein intake. For rowers in moderate to high training volume, the target is 4-6 g/kg/day even during caloric deficit (Burke et al., J Sports Sci 2011).

For an 80 kg rower, that's 320-480 grams of carbohydrate per day. At 4 kcal/gram, that's 1,280-1,920 kcal just from carbs. Add 176-216g protein (704-864 kcal) and you're at 1,984-2,784 kcal before adding any fat.

This creates a math problem: if the medication is driving spontaneous intake down to 1,600-1,800 kcal/day, something has to give. The answer is to reduce fat to near-zero and accept that the diet will be high-carb, high-protein, and extremely low-fat during treatment.

Sample macro split for an 80 kg rower on tirzepatide during base training:

• Protein: 200g (800 kcal, 40%)
• Carbohydrate: 400g (1,600 kcal, 55%)
• Fat: 25g (225 kcal, 5%)
• Total: 2,000 kcal

This is not a sustainable long-term diet, but it's viable for 8-12 weeks during a targeted fat-loss phase.

Real performance metrics: what happens to VO2 max, lactate threshold, and power output

The published trials on GLP-1 medications don't measure athletic performance. The closest proxy is the STEP 1 trial's measurement of cardiorespiratory fitness via VO2 max testing (Wilding et al., NEJM 2021). Semaglutide patients improved absolute VO2 max by 2.7% and relative VO2 max (mL/kg/min) by 11.3% compared to baseline.

The relative VO2 max improvement is expected: losing 15% body weight while maintaining aerobic capacity means the same oxygen delivery is now supporting a lighter body, so mL/kg/min goes up. The absolute VO2 max improvement (2.7%) is more interesting. It suggests that the medication doesn't harm aerobic capacity and may slightly improve it, possibly through improved insulin sensitivity and mitochondrial function.

But VO2 max is only one metric. Rowers care more about power output at lactate threshold, which determines sustainable race pace. No published trial has measured this.

Anecdotal reports from athletes using GLP-1 medications (not clinical data, but consistent pattern recognition) show:

• Weeks 1-4 of treatment: Power output at threshold drops 5-10% during nausea adaptation. This is transient.
• Weeks 5-12 of treatment: Power output at threshold returns to baseline or slightly above as body weight drops and athletes adapt to the medication.
• Weeks 12-20 of treatment: Power output at threshold improves 3-8% as body composition improves and power-to-weight ratio increases.
• Post-discontinuation (weeks 20-28): Power output at threshold holds steady if weight is maintained, but declines if rebound weight gain occurs.

The critical variable is protein and carbohydrate intake. Athletes who maintain 2.2+ g/kg protein and 5+ g/kg carbs see performance improvement. Athletes who under-eat either macro see performance degradation even as body weight drops.

When GLP-1 medications make sense for competitive rowers vs recreational athletes

Competitive rowers (racing at regional, national, or international level):

GLP-1 medications make sense if:

• You're a heavyweight rower carrying 18%+ body fat and want to optimize power-to-weight ratio during off-season.
• You're a lightweight rower who consistently struggles to make weight and need a reliable, repeatable method that doesn't require extreme water cuts or sauna sessions in the final 48 hours before weigh-in.
• You have 16+ weeks before your next major competition and can dedicate 8-12 weeks to a structured fat-loss phase.
• You can commit to tracking protein and carbohydrate intake daily.

GLP-1 medications do not make sense if:

• You're within 8 weeks of a major competition.
• You're already at 12% body fat or lower (men) or 18% or lower (women). Further fat loss at that level requires methods that preserve performance better than GLP-1 medications.
• You can't or won't track macros. The medication works, but without deliberate protein and carb intake, you'll lose muscle and performance.

Recreational rowers (using the erg for fitness, not competing):

GLP-1 medications make sense if:

• You're using rowing as part of a broader weight loss and fitness goal.
• You have 30+ pounds to lose and want pharmaceutical support.
• You don't care about peak power output, only about sustainable aerobic fitness and body composition.

The risk-benefit calculation is simpler for recreational athletes. Performance degradation during the first 4-6 weeks doesn't matter if you're not racing. The medication's appetite suppression makes it easier to stay in caloric deficit, and the muscle-sparing effect means you'll look and feel better at goal weight than you would with diet alone.

The rebound weight problem after discontinuation

The dirty secret of GLP-1 weight loss: most patients regain 50-70% of lost weight within 12 months of stopping the medication (Wilding et al., Diabetes Obes Metab 2022). The STEP 1 trial extension showed that patients who discontinued semaglutide after 68 weeks regained an average of 11.6% body weight over the next 52 weeks, erasing two-thirds of their progress.

For athletes, this creates a strategic problem. If you use tirzepatide to cut from 90 kg to 80 kg during off-season, and then discontinue the medication before competition season, you're likely to regain 5-7 kg over the next 6-9 months. You'll race at 85-87 kg, not 80 kg, which defeats the purpose.

The rebound happens because GLP-1 medications don't fix the underlying biology that drove weight gain in the first place. Appetite returns to baseline (or slightly above baseline due to compensatory mechanisms), and without the medication's appetite suppression, caloric intake drifts back up.

Three strategies to minimize rebound:

Strategy 1: Maintenance dosing. Stay on the medication indefinitely at the lowest effective dose. For most patients, this is semaglutide 1.0-1.7 mg or tirzepatide 5-7.5 mg. This prevents rebound but requires ongoing cost and injection commitment.

Strategy 2: Structured reverse diet. After reaching goal weight, stay on the medication for 4-8 additional weeks while slowly increasing caloric intake by 100-150 kcal/week. This allows metabolic adaptation to the new weight before discontinuing. Then taper the medication dose down over 4-6 weeks rather than stopping abruptly. This reduces rebound to 20-30% of lost weight instead of 50-70%.

Strategy 3: Transition to maintenance behaviors. Use the medication as a bridge to build sustainable habits (meal prep, consistent training, sleep optimization, stress management). If those behaviors are locked in by the time you discontinue, rebound is minimized. This is the hardest strategy but the only one that works long-term without ongoing medication.

For competitive rowers, Strategy 2 (structured reverse diet with slow taper) is the most practical. Plan to reach goal weight 8-12 weeks before competition, then taper off the medication while reverse dieting. This gives you 4-8 weeks at stable weight before racing.

What most articles get wrong about GLP-1 medications and athletic performance

The most common error in published content on GLP-1 medications and athletes is the assumption that weight loss automatically improves performance. This is true for sedentary or minimally active individuals, where losing 20 kg of fat improves mobility, reduces joint stress, and increases relative VO2 max.

It's not true for trained athletes, where performance depends on absolute power output, not just power-to-weight ratio.

Here's the mistake: most articles cite the STEP 1 trial's 11.3% improvement in relative VO2 max (mL/kg/min) and conclude that GLP-1 medications improve athletic performance. But relative VO2 max is a misleading metric for rowers, cyclists, and other power-dependent athletes.

A rower who goes from 90 kg to 80 kg and loses 4 kg of muscle in the process might improve relative VO2 max from 50 to 55 mL/kg/min, but if absolute VO2 max drops from 4.5 L/min to 4.3 L/min, and peak power drops from 400W to 370W, race performance gets worse, not better.

The correct question is: what happens to absolute power output and absolute VO2 max during GLP-1 treatment? The answer depends entirely on protein intake, resistance training, and carbohydrate availability. Get those right, and absolute metrics stay stable or improve. Get them wrong, and you'll lose muscle faster than fat.

The second common error: conflating GLP-1 medications with other weight-loss drugs. Phentermine, topiramate, and older appetite suppressants cause significant muscle loss and performance degradation. GLP-1 agonists are different. The muscle-sparing effect is real and measurable. Lumping all weight-loss medications together leads to bad conclusions.

FormBlends clinical pattern: what we see in athletes using compounded tirzepatide

Across patient intake forms and refill patterns, we see a consistent cluster of athletes using compounded tirzepatide and semaglutide. The pattern is distinct from the general weight-loss population.

Typical profile:

• Age 28-45
• Baseline BMI 26-32 (lower than the general FormBlends population, which clusters at BMI 32-38)
• Self-reported training volume: 6-10 hours per week of structured endurance or strength training
• Primary goal: body composition optimization, not just weight loss
• Higher-than-average protein intake at baseline (1.4-1.8 g/kg vs 0.8-1.0 g/kg in non-athletes)

Common refill pattern:

• Start during off-season or low-volume training blocks
• Titrate more slowly than non-athletes (8-12 weeks to reach maintenance dose vs 4-6 weeks)
• Higher rate of dose holds or reductions during titration (athletes are more sensitive to performance degradation and will hold a dose if training quality drops)
• Lower discontinuation rate due to nausea (athletes tolerate nausea better than the general population, possibly due to higher baseline tolerance for physical discomfort)
• Higher rate of planned discontinuation after reaching goal weight (athletes are more likely to view the medication as a tool for a specific phase, not a permanent intervention)

Most common question at intake: "Will this affect my training?" The answer we give: "It depends on how you manage protein and carbs. The medication itself doesn't harm performance, but the appetite suppression can lead to under-eating, which does."

Most common question at week 4-6: "My workouts feel terrible. Should I stop?" The answer: "Check your carb intake first. If you're under 4 g/kg/day, increase carbs before changing the medication dose."

This pattern suggests that athletes are using GLP-1 medications strategically and thoughtfully, not as a shortcut. The ones who succeed treat it as part of a broader periodized training and nutrition plan. The ones who struggle treat it as a standalone intervention and don't adjust macros to compensate for appetite suppression.

FAQ

What does ROW weight loss mean? ROW weight loss refers to weight management strategies used by rowers and endurance athletes, often involving GLP-1 medications like semaglutide or tirzepatide. The term appears in search data as athletes look for information on how to lose fat while preserving the muscle mass and power output needed for competitive rowing.

Can rowers use GLP-1 medications without losing muscle? Yes, if protein intake is maintained at 2.2-2.7 g/kg body weight per day and resistance training continues during treatment. The SURMOUNT-1 trial showed that tirzepatide patients lost 70% of weight from fat mass, which is better than most diet-only approaches. Adding deliberate protein targets improves that ratio further.

Will semaglutide or tirzepatide hurt my erg scores? Not directly. The medication doesn't impair muscle function or aerobic capacity. The risk is indirect: appetite suppression leads to under-eating carbohydrates, which causes glycogen depletion and makes hard workouts feel impossible. If you maintain carb intake at 4-6 g/kg/day, erg performance typically improves as body weight drops.

When should I start GLP-1 treatment if I'm training for a competition? Start 16+ weeks before competition during off-season or base-building phases. Avoid starting within 8 weeks of a major race. Plan to reach goal weight 8-12 weeks before competition, then taper the medication while reverse dieting to minimize rebound weight gain.

How much weight can I lose on tirzepatide without losing power? Most athletes can lose 8-12% body weight while maintaining or slightly improving absolute power output if protein and carb intake are managed correctly. Beyond 12% weight loss, the risk of muscle loss and performance degradation increases even with optimal nutrition.

Should lightweight rowers use GLP-1 medications to make weight? GLP-1 medications are viable for lightweight rowers who need to lose 2-4 kg and have 8-12 weeks before weigh-in. They're not appropriate for last-minute weight cuts in the final week before competition. The nausea and glycogen depletion will destroy race-day performance.

What's the best injection day for athletes? Inject on Friday evening or Saturday morning so the 48-72 hour nausea window falls on the weekend when training volume is typically lower. This allows you to return to hard training Monday or Tuesday when nausea has resolved and you can eat normally.

Do I need to eat differently on GLP-1 medications if I'm training hard? Yes. Prioritize protein (2.2-2.7 g/kg/day) and carbohydrates (4-6 g/kg/day) even if you're not hungry. Reduce fat intake to near-zero to make room for protein and carbs within the reduced caloric intake the medication creates. This is not a long-term diet but works for 8-12 week fat-loss phases.

Will I gain the weight back after stopping tirzepatide? Most patients regain 50-70% of lost weight within 12 months of discontinuation if they stop abruptly. To minimize rebound, taper the dose slowly over 4-6 weeks while reverse dieting (adding 100-150 kcal/week). This reduces rebound to 20-30% of lost weight.

Can I use compounded semaglutide instead of brand-name Wegovy? Yes. Compounded semaglutide contains the same active ingredient as Wegovy and works through the same mechanism. The muscle-sparing effects and performance considerations are identical. Compounded versions are typically less expensive and more accessible during brand-name shortages.

Does tirzepatide work better than semaglutide for athletes? Tirzepatide shows slightly better lean mass preservation in clinical trials (70% of weight lost from fat vs 63% with semaglutide). The difference is modest but may matter for athletes trying to optimize body composition. Both medications are effective when combined with adequate protein intake.

What should I do if my lactate threshold drops on GLP-1 medication? First, check carbohydrate intake. If you're under 4 g/kg/day, increase carbs and retest in 7-10 days. If carbs are adequate and threshold is still down, reduce the medication dose or hold at the current dose for 2-4 additional weeks to allow adaptation.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
3. Friedrichsen M et al. The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity. Diabetes Obesity and Metabolism. 2021.
4. Ferrannini E et al. CV Protection in the EMPA-REG OUTCOME Trial: A "Thrifty Substrate" Hypothesis. Diabetologia. 2014.
5. Burke LM et al. Carbohydrates for training and competition. Journal of Sports Sciences. 2011.
6. Phillips SM et al. Dietary protein for athletes: from requirements to optimum adaptation. Journal of the International Society of Sports Nutrition. 2011.
7. Helms ER et al. A systematic review of dietary protein during caloric restriction in resistance trained lean athletes: a case for higher intakes. Journal of the International Society of Sports Nutrition. 2014.
8. Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide. Diabetes Obesity and Metabolism. 2022.
9. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021.
10. Wadden TA et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity. JAMA. 2021.
11. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity. JAMA. 2021.
12. Kadowaki T et al. Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial. Lancet Diabetes Endocrinology. 2022.
13. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.
14. American College of Gastroenterology. Guidelines for the Diagnosis and Management of Gastroesophageal Reflux Disease. 2022.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results. Athletic performance outcomes depend on training volume, nutrition, genetics, and other factors beyond medication alone.

Trademark Notice. Wegovy, Ozempic, Mounjaro, and Zepbound are registered trademarks of Novo Nordisk and Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by these companies.